MindMed Acquires HealthMode For $41.6 Million
MindMed (NEO: MMED) this morning announced that it will be acquiring that of HealthMode in a largely stock-based transaction. HealthMode
Read more
MindMed
MindMed Begins Study On LSD Neutralizer Technology
MindMed (NEO: MMED) this morning announced that it has begun a study on what it refers to as “LSD neutralizer
Read more
MindMed Launches Clinical Trial Focused On Combining LSD With MDMA
Mind Medicine (NEO: MMED) has begun the first clinical trials focused on combining MDMA and LSD. The trials, to be
Read more
Mind Medicine Raises $92.1 Million Via Bought Deal Financing
Mind Medicine (NEO: MMED) has closed its previously announced bought deal financing, raising nearly double the initial $50.0 million the
Read more
MindMed Closes $34.5 Million Financing, Cash Reserves Said To Be At $85 Million
Mind Medicine (NEO: MMED) has completed its previously announced bought deal private placement, raising gross proceeds of $34.5 million. The
Read more
Mind Medicine Returns To Trough For Further $25.0 Million
Mind Medicine (NEO: MMED) continues to take investor dollars, this morning announcing a bought deal private placement for $25.0 million.
Read more
Mind Medicine: Canaccord Maintains Ratings Following Financial Results
On Friday, November 13th, Mind Medicine (NEO: MMED) reported their third quarter 2020 financial results. Tania Gonsalves, Canaccord Genuity’s biotechnology
Read more
Canaccord Raises Mind Medicine’s Price Target To $2.00 Following Financing
This morning, Canaccord Genuity raised its 12-month price target on Mind Medicine (NEO: MMED) from C$1.75 to C$2.00 while reiterating
Read more
Mind Medicine: Canaccord Genuity Initiates Coverage With C$1.75 Price Target
Yesterday, Canaccord initiated coverage on Mind Medicine (NEO: MMED) with a Speculative Buy rating and a C$1.75 price target. Canaccord’s
Read more
MindMed Adds MDMA To R&D Pipeline
Mind Medicine, also known as MindMed (NEO: MMED) this morning announced that it is branching out its research and development
Read more